Breaking News

Emerald Health, Lonza Enter Large-Scale Mfg. Pact

Lonza will synthesize the API drug substance and develop the CBD drug product as liquid-filled capsules

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emerald Health Pharmaceuticals and Lonza have entered an agreement for the large-scale manufacturing of a new synthetic derivative of cannabidiol (CBD) and its oral drug product for the treatment of multiple sclerosis (MS) and systemic scleroderma, also known as systemic sclerosis (SSc). Lonza Pharma & Biotech will synthesize the API drug substance (VCE-004.8) and develop the drug product (EHP-101) as liquid-filled capsules.   The development program will utilize Lonza’s global network: AP...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters